Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
HUMAN PLASMA PROTEIN >90% GAMMA GLOBULIN
Baxter Healthcare Limited
HUMAN PLASMA PROTEIN >90% GAMMA GLOBULIN
1.6g/10ml %w/v
Solution for Injection
Withdrawn
2007-02-22
PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Gammabulin S/D 160 mg/ml Solution for injection, 10 ml 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Human Normal Immunoglobulin (SC/IMIg) 1 ml solution contains: Human protein 160 mg. (of which at least 90 % are immunoglobulin). Distribution of IgG subclasses: Maximum IgA content: 4.8 mg/ml. 1 vial of 10 ml contains 1600 mg human protein (of which at least 90 % are immunoglobulin). For excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for Injection The product is a clear or slightly opalescent, colourless to pale yellow solution. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Replacement therapy in patients with primary or secondary immunodeficiency. o Congenital agammagloculinaemia and hypogammaglobulinaemia. o Common variable immunodeficiency. o Severe combined immunodeficiency. o IgG subclass deficiencies with or without concomitant IgA deficiency. o Specific antibody deficiencies. Replacement therapy in secondary immunodeficiency disorders such as hypogammaglobulinaemia or low levels if IgG due to low grade B-cell tumours. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Replacement therapy: human normal immunoglobulin i.m. may prevent serious infection in patients with immunoglobulin deficiency. The dosage should be adjusted to maintain an approximate level of 2g/I of circulating IgG. The usual posology consists of 0.66 ml/kg body weight (100 mg/kg) given every 3 to 4 weeks, with a double dose IgG1 45-75 % IgG2 20-45 % IgG3 3-10 % IgG4 2-8 % IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 18/08/2006_ _CRN 2026883_ _page number: 1_ given at onset of therapy. 4.2.1 POSOLOGY The dose and dosage regimen is dependent on the indicat Read the complete document